Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient

키워드

참고문헌 (72)

1. Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 62, pp.593~602 (2005)
2. Kessler RC, "Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication(NCS-R)", Arch Gen Psychiatry, 62, pp.617~627 (2005)
3. King M, "Prevalence of common mental disorders in general practice attendees across Europe", Br J Psychiatry, 192, pp.362~367 (2008)
4. Marchesi C, "Pharmacological management of panic disorder", Neuropsychiatr Dis Treat, 4, pp.93~106 (2008)
5. Masi G, "Panic disorder in clinically referred children and adolescents", Child Psychiatry Hum Dev, 31, pp.139~151 (2000)
6. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR" (2000), American Psychiatric Association
7. Kessler RC, "The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 63, pp.415~424 (2006)
8. Gorman JM, "Neuroanatomical hypothesis of panic disorder, revised", Am J Psychiatry, 157, pp.493~505 (2000)
9. Freire RC, "New treatment options for panic disorder : clinical trials from 2000 to 2010", Expert Opin Pharmacother, 12, pp.1419~1428 (2011)
10. Perna G, "Emerging drugs for panic disorder", Expert Opin Emerg Drugs, 16, pp.631~645 (2011)
11. Nardi AE, "Panic disorder and control of breathing", Respir Physiol Neurobiol, 167, pp.133~143 (2009)
12. Gorman JM, "A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders", J Neuropsychiatry Clin Neurosci, 22, pp.256~264 (2010)
13. Klein DF, "False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis", Arch Gen Psychiatry, 50, pp.306~317 (1993)
14. Esquivel G, "Acids in the brain : a factor in panic", J Psychopharmacol, 24, pp.639~647 (2010)
15. Austin D, "Managing panic disorder in general practice", Aust Fam Physician, 34, pp.563~571 (2005)
16. Marchesi C, "Personality disorders and response to medication treatment in panic disorder : a 1-year naturalistic study", Prog NeuroPsychopharmacol Biol Psychiatry, 30, pp.1240~1245 (2006)
17. Bakker A, "Evidence-based pharmacotherapy of panic disorder", Int J Neuropsychopharmacol, 8, pp.473~482 (2005)
18. Roy-Byrne PP, "Panic disorder", Lancet, 368, pp.1023~1032 (2006)
19. Batelaan NM, "Evidence-based pharmacotherapy of panic disorder : an update", Int J Neuropsychopharmacol, 15, pp.403~415 (2012)
20. Bystritsky A, "Clinical and subthreshold panic disorder", Depress Anxiety, 27, pp.381~389 (2010)
21. Kroenke K, "Patients presenting with somatic complaints : epidemiology, psychiatric comorbidity and management", Int J Methods Psychiatr Res, 12, pp.34~43 (2003)
22. Starcevic V, "Treatment of panic disorder : recent developments and current status", Expert Rev Neurother, 8, pp.1219~1232 (2008)
23. "National Institute for Health and Clinical Excellence (NICE)", NICE, ~ (2011)
24. Mitte K, "A meta-analysis of the efficacy of psycho-and pharmacotherapy in panic disorder with and without agoraphobia", J Affect Disord, 88, pp.27~45 (2005)
25. Imai H, "Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults", Cochrane Database Syst Rev, 10, pp.CD011170~ (2016)
26. Gould RA, "A meta-analysis of treatment outcome for panic disorder", Clin Psychol Rev, 15, pp.819~844 (1995)
27. Bighelli I, "Antidepressants and benzodiazepines for panic disorder in adults", Cochrane Database Syst Rev, 9, pp.CD011567~ (2016)
28. Otto MW, "An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder", Am J Psychiatry, 158, pp.1989~1992 (2001)
29. Bakker A, "SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis", Acta Psychiatr Scand, 106, pp.163~167 (2002)
30. Andrisano C, "Newer antidepressants and panic disorder : a meta-analysis", Int Clin Psychopharmacol, 28, pp.33~45 (2013)
31. American Psychiatric Association, "Practice guideline for the treatment of patients with panic disorder" (2009), American Psychiatric Association
32. Bandelow B, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision", World J Biol Psychiatry, 9, pp.248~312 (2008)
33. Serretti A, "Novel antidepressants and panic disorder : evidence beyond current guidelines", Neuropsychobiology, 63, pp.1~7 (2011)
34. Freire RC, "Current pharmacological interventions in panic disorder", CNS Neurol Disord Drug Targets, 13, pp.1057~1065 (2014)
35. Susman J, "The role of high-potency benzodiazepines in the treatment of panic disorder", Prim Care Companion J Clin Psychiatry, 7, pp.5~11 (2005)
36. Ferguson JM, "SSRI antidepressant medications : adverse effects and tolerability", Prim Care Companion J Clin Psychiatry, 3, pp.22~27 (2001)
37. Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
38. Perna G, "Novel investigational therapeutics for panic disorder", Expert Opin Investig Drugs, 24, pp.491~505 (2015)
39. Gupta S, "Duloxetine : review of its pharmacology, and therapeutic use in depression and other psychiatric disorders", Ann Clin Psychiatry, 19, pp.125~132 (2007)
40. Simon NM, "Open-label support for duloxetine for the treatment of panic disorder", CNS Neurosci Ther, 15, pp.19~23 (2009)
41. Anttila SA, "A review of the pharmacological and clinical profile of mirtazapine", CNS Drug Rev, 7, pp.249~264 (2001)
42. Carpenter LL, "Clinical experience with mirtazapine in the treatment of panic disorder", Ann Clin Psychiatry, 11, pp.81~86 (1999)
43. Boshuisen ML, "The effect of mirtazapine in panic disorder : an open label pilot study with a single-blind placebo run-in period", Int Clin Psychopharmacol, 16, pp.363~368 (2001)
44. Carli V, "Mirtazapine in the treatment of panic disorder", Arch Gen Psychiatry, 59, pp.661~662 (2002)
45. Sarchiapone M, "Mirtazapine in the treatment of panic disorder : an open-label trial", Int Clin Psychopharmacol, 18, pp.35~38 (2003)
46. Ribeiro L, "Mirtazapine versus fluoxetine in the treatment of panic disorder", Braz J Med Biol Res, 34, pp.1303~1307 (2001)
47. Montañes-Rada F, "Venlafaxine, serotonin syndrome, and differential diagnoses", J Clin Psychopharmacol, 25, pp.101~102 (2005)
48. Wong EH, "Reboxetine : a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor", Biol Psychiatry, 47, pp.818~829 (2000)
49. Dannon PN, "The efficacy of reboxetine in the treatment-refractory patients with panic disorder : an open label study", Hum Psychopharmacol, 17, pp.329~333 (2002)
50. Versiani M, "Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder", J Clin Psychiatry, 63, pp.31~37 (2002)
51. Seedat S, "Reboxetine and citalopram in panic disorder : a single-blind, cross-over, flexible-dose pilot study", Int Clin Psychopharmacol, 18, pp.279~284 (2003)
52. Bertani A, "Comparison of the treatment with paroxetine and reboxetine in panic disorder : a randomized, single-blind study", Pharmacopsychiatry, 37, pp.206~210 (2004)
53. Davis R, "Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression", Drugs, 53, pp.608~636 (1997)
54. DeMartinis NA, "An open-label trial of nefazodone in high comorbidity panic disorder", J Clin Psychiatry, 57, pp.245~248 (1996)
55. Bystritsky A, "Pilot open-label study of nefazodone in panic disorder", Depress Anxiety, 10, pp.137~139 (1999)
56. Papp LA, "Efficacy of open-label nefazodone treatment in patients with panic disorder", J Clin Psychopharmacol, 20, pp.544~546 (2000)
57. Grant S, "Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia", Drugs, 48, pp.253~273 (1994)
58. Prosser JM, "A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks : a randomized, single-blind study", BMC Psychiatry, 9, pp.25~ (2009)
59. Kim H, "A review of the possible relevance of inositol and the phosphatidylinositol second messenger system(PI-cycle)to psychiatric disorders--focus on magnetic resonance spectroscopy(MRS)studies", Hum Psychopharmacol, 20, pp.309~326 (2005)
60. Benjamin J, "Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder", Am J Psychiatry, 152, pp.1084~1086 (1995)
61. Palatnik A, "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder", J Clin Psychopharmacol, 21, pp.335~339 (2001)
62. Shekhar A, "LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats", Neuropharmacology, 39, pp.1139~1146 (2000)
63. Javitt DC, "Glutamate as a therapeutic target in psychiatric disorders", Mol Psychiatry, 9, pp.984~997 (2004)
64. Grillon C, "Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist(LY354740)in the fear-potentiated startle paradigm in humans", Psychopharmacology(Berl), 168, pp.446~454 (2003)
65. Schoepp DD, "LY354740, an mGlu2", 3 receptor agonist as a novel approach to treat anxiety, Stress, pp.2003, 6[DOI]
66. Bergink V, "Metabotropic glutamate II receptor agonists in panic disorder : a double blind clinical trial with LY354740", Int Clin Psychopharmacol, 20, pp.291~293 (2005)
67. Rorick-Kehn LM, "Improved bioavailability of the mGlu2", 3 receptor agonist LY354740 using a prodrug strategy : in vivo pharmacology of LY544344, 2006, pp.316, 905~913
68. Kellner M, "Effects of a metabotropic glutamate(2", 3) receptor agonist (LY544344, Psychopharmacology (Berl), pp.2005, 179[DOI]
69. Crepeau AZ, "Levetiracetam : a comprehensive review", Expert Rev Neurother, 10, pp.159~171 (2010)
70. Mula M, "The role of anticonvulsant drugs in anxiety disorders : a critical review of the evidence", J Clin Psychopharmacol, 27, pp.263~272 (2007)
71. Lamberty Y, "Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat", Eur J Pharmacol, 469, pp.97~102 (2003)
72. Papp LA, "Safety and efficacy of levetiracetam for patients with panic disorder : results of an open-label, fixed-flexible dose study", J Clin Psychiatry, 67, pp.1573~1576 (2006)

관련 논문AI추천